LIFEVANTAGE CORP (LFVN) Free cash flow
- Free cash flow · 12 months (USD): Value $6.67M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value 3.65%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $6.67M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $10.24M − $3.57M ≈ $6.67M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | 3.65% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $6.67M ÷ $182.59M × 100 ≈ 3.65% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $10.24M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 2.02× | Operating cash flow / net income. Period ending 2026-06-30. $10.24M ÷ $5.07M ≈ 2.02× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | 10.24M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 3.57M USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | 6.67M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 182.59M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | 5.07M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $6.67M | (m) | $10.24M | $3.57M | (m) | $182.59M | (m) | $5.07M | (m) | (m) | 3.65% | 2.02× |
| 2026-03-31 | $3.77M | (m) | $6.51M | $2.73M | (m) | $195.32M | (m) | $5.75M | (m) | (m) | 1.93% | 1.13× |
| 2025-12-31 | $1.70M | (m) | $3.75M | $2.05M | (m) | $210.05M | (m) | $7.86M | (m) | (m) | 0.81% | 0.48× |
| 2025-09-30 | $8.70M | (m) | $10.16M | $1.46M | (m) | $228.88M | (m) | $10.13M | (m) | (m) | 3.80% | 1.00× |
| 2025-06-30 | $10.51M | (m) | $11.88M | $1.37M | (m) | $228.53M | (m) | $9.80M | (m) | (m) | 4.60% | 1.21× |
| 2025-03-31 | $11.98M | (m) | $13.43M | $1.45M | (m) | $222.35M | (m) | $9.15M | (m) | (m) | 5.39% | 1.47× |
| 2024-12-31 | $12.88M | (m) | $14.29M | $1.41M | (m) | $212.15M | (m) | $7.34M | (m) | (m) | 6.07% | 1.95× |
| 2024-09-30 | $5.39M | (m) | $6.85M | $1.46M | (m) | $196.01M | (m) | $4.13M | (m) | (m) | 2.75% | 1.66× |
| 2024-06-30 | $9.95M | (m) | $12.20M | $2.25M | (m) | $200.16M | (m) | $2.94M | (m) | (m) | 4.97% | 4.15× |
| 2024-03-31 | $10.90M | (m) | $13.38M | $2.48M | (m) | $205.45M | (m) | $3.60M | (m) | (m) | 5.30% | 3.72× |
| 2023-12-31 | $10.55M | (m) | $13.73M | $3.18M | (m) | $210.95M | (m) | $2.96M | (m) | (m) | 5.00% | 4.64× |
| 2023-09-30 | $9.46M | (m) | $12.94M | $3.47M | (m) | $212.99M | (m) | $2.56M | (m) | (m) | 4.44% | 5.06× |
| 2023-06-30 | $3.76M | (m) | $6.83M | $3.07M | (m) | $213.40M | (m) | $2.54M | (m) | (m) | 1.76% | 2.69× |
| 2023-03-31 | $3.02M | (m) | $5.84M | $2.82M | (m) | $210.12M | (m) | $-842.00K | (m) | (m) | 1.44% | -6.94× |
| 2022-12-31 | $878.00K | (m) | $3.07M | $2.19M | (m) | $206.38M | (m) | $-723.00K | (m) | (m) | 0.43% | -4.25× |
| 2022-09-30 | $4.27M | (m) | $6.15M | $1.88M | (m) | $204.91M | (m) | $414.00K | (m) | (m) | 2.08% | 14.85× |
| 2022-06-30 | $6.43M | (m) | $7.96M | $1.53M | (m) | $206.36M | (m) | $3.12M | (m) | (m) | 3.12% | 2.55× |
| 2022-03-31 | $11.81M | (m) | $13.55M | $1.74M | (m) | $210.19M | (m) | $9.44M | (m) | (m) | 5.62% | 1.44× |
| 2021-12-31 | $12.83M | (m) | $15.94M | $3.11M | (m) | $211.76M | (m) | $10.03M | (m) | (m) | 6.06% | 1.59× |
| 2021-09-30 | $14.63M | (m) | $17.79M | $3.16M | (m) | $218.58M | (m) | $13.76M | (m) | (m) | 6.69% | 1.29× |
| 2021-06-30 | $12.53M | (m) | $16.27M | $3.74M | (m) | $220.18M | (m) | $12.89M | (m) | (m) | 5.69% | 1.26× |
| 2021-03-31 | $13.41M | (m) | $17.25M | $3.83M | (m) | $224.77M | (m) | $11.81M | (m) | (m) | 5.97% | 1.46× |
| 2020-12-31 | $14.82M | (m) | $17.40M | $2.58M | (m) | $229.28M | (m) | $11.75M | (m) | (m) | 6.46% | 1.48× |
| 2020-09-30 | $17.84M | (m) | $20.73M | $2.89M | (m) | $231.51M | (m) | $12.24M | (m) | (m) | 7.71% | 1.69× |
| 2020-06-30 | $15.64M | (m) | $18.33M | $2.68M | (m) | $232.91M | (m) | $11.55M | (m) | (m) | 6.72% | 1.59× |
| 2020-03-31 | $13.04M | (m) | $15.96M | $2.92M | (m) | $229.72M | (m) | $11.63M | (m) | (m) | 5.68% | 1.37× |
| 2019-12-31 | $12.74M | (m) | $16.61M | $3.87M | (m) | $229.65M | (m) | $11.75M | (m) | (m) | 5.55% | 1.41× |
| 2019-09-30 | $8.79M | (m) | $11.96M | $3.17M | (m) | $226.58M | (m) | $8.28M | (m) | (m) | 3.88% | 1.44× |
| 2019-06-30 | $15.28M | (m) | $17.79M | $2.51M | (m) | $225.96M | (m) | $7.43M | (m) | (m) | 6.76% | 2.39× |
| 2019-03-31 | $13.30M | (m) | $16.28M | $2.97M | (m) | $223.82M | (m) | $6.51M | (m) | (m) | 5.94% | 2.50× |
| 2018-12-31 | $12.71M | (m) | $15.52M | $2.80M | (m) | $218.37M | (m) | $6.37M | (m) | (m) | 5.82% | 2.44× |
| 2018-09-30 | $9.56M | (m) | $13.12M | $3.56M | (m) | $209.69M | (m) | $5.86M | (m) | (m) | 4.56% | 2.24× |
| 2018-06-30 | $8.61M | (m) | $13.26M | $4.65M | (m) | $203.20M | (m) | $5.76M | (m) | (m) | 4.24% | 2.30× |
| 2018-03-31 | $5.80M | (m) | $9.76M | $3.96M | (m) | $199.81M | (m) | $2.85M | (m) | (m) | 2.90% | 3.42× |
| 2017-12-31 | $3.24M | (m) | $6.18M | $2.94M | (m) | $194.26M | (m) | $1.28M | (m) | (m) | 1.67% | 4.83× |
| 2017-09-30 | $4.08M | (m) | $6.22M | $2.14M | (m) | $193.72M | (m) | $1.25M | (m) | (m) | 2.11% | 5.00× |
| 2017-06-30 | $5.54M | (m) | $6.60M | $1.05M | (m) | $199.49M | (m) | $1.61M | (m) | (m) | 2.78% | 4.10× |
| 2017-03-31 | $3.88M | (m) | $4.41M | $527.00K | (m) | $201.88M | (m) | $3.87M | (m) | (m) | 1.92% | 1.14× |
| 2016-12-31 | $2.11M | (m) | $2.58M | $466.00K | (m) | $213.03M | (m) | $4.82M | (m) | (m) | 0.99% | 0.54× |
| 2016-09-30 | $5.37M | (m) | $6.03M | $653.00K | (m) | $216.08M | (m) | $6.13M | (m) | (m) | 2.49% | 0.98× |
| 2016-06-30 | $5.42M | (m) | $5.99M | $562.00K | (m) | $206.54M | (m) | $6.02M | (m) | (m) | 2.63% | 0.99× |
| 2016-03-31 | $9.90M | (m) | $10.46M | $555.00K | (m) | $198.81M | (m) | $3.90M | (m) | (m) | 4.98% | 2.68× |
| 2015-12-31 | $13.13M | (m) | $13.76M | $629.00K | (m) | $187.80M | (m) | $3.46M | (m) | (m) | 6.99% | 3.97× |
| 2015-09-30 | $10.07M | (m) | $11.00M | $926.00K | (m) | $184.06M | (m) | $3.34M | (m) | (m) | 5.47% | 3.30× |
| 2015-06-30 | $12.06M | (m) | $13.22M | $1.16M | (m) | $190.34M | (m) | $6.99M | (m) | (m) | 6.34% | 1.89× |
| 2015-03-31 | $9.56M | (m) | $10.89M | $1.33M | (m) | $201.07M | (m) | $9.11M | (m) | (m) | 4.75% | 1.20× |
| 2014-12-31 | $11.05M | (m) | $13.15M | $2.10M | (m) | $210.98M | (m) | $11.03M | (m) | (m) | 5.24% | 1.19× |
| 2014-09-30 | $10.47M | (m) | $12.31M | $1.84M | (m) | $214.27M | (m) | $12.84M | (m) | (m) | 4.89% | 0.96× |
| 2014-06-30 | $10.21M | (m) | $12.11M | $1.90M | (m) | $213.97M | (m) | $11.38M | (m) | (m) | 4.77% | 1.06× |
| 2014-03-31 | $8.65M | (m) | $10.77M | $2.13M | (m) | $209.44M | (m) | $8.85M | (m) | (m) | 4.13% | 1.22× |
| 2013-12-31 | $9.35M | (m) | $11.22M | $1.87M | (m) | $204.75M | (m) | $9.77M | (m) | (m) | 4.57% | 1.15× |
| 2013-09-30 | $10.79M | (m) | $14.60M | $3.81M | (m) | $206.65M | (m) | $6.70M | (m) | (m) | 5.22% | 2.18× |
| 2013-06-30 | $5.58M | (m) | $10.66M | $5.08M | (m) | $208.18M | (m) | $7.61M | (m) | (m) | 2.68% | 1.40× |
| 2013-03-31 | $12.71M | (m) | $17.79M | $5.07M | (m) | $201.27M | (m) | $12.62M | (m) | (m) | 6.32% | 1.41× |
| 2012-12-31 | $12.66M | (m) | $17.71M | $5.05M | (m) | $187.11M | (m) | $4.36M | (m) | (m) | 6.77% | 4.06× |
| 2012-09-30 | $13.56M | (m) | $16.96M | $3.41M | (m) | $158.96M | (m) | $12.91M | (m) | (m) | 8.53% | 1.31× |
| 2012-06-30 | $17.19M | (m) | $19.39M | $2.19M | (m) | $126.18M | (m) | $12.47M | (m) | (m) | 13.63% | 1.55× |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | $4.56M | (m) | $4.68M | $122.30K | (m) | $38.92M | (m) | $-50.79M | (m) | (m) | 11.71% | -0.09× |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |